Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K
delta/gamma inhibitor in patients with hematologic malignancies.